Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital

Jennifer R Bellis, Jamie J Kirkham, Signe Thiesen, Elizabeth J Conroy, Louise E Bracken, Helena L Mannix, Kim A Bird, Jennifer C Duncan, Matthew Peak, Mark A Turner, Rosalind L Smyth, Anthony J Nunn, Munir Pirmohamed, Jennifer R Bellis, Jamie J Kirkham, Signe Thiesen, Elizabeth J Conroy, Louise E Bracken, Helena L Mannix, Kim A Bird, Jennifer C Duncan, Matthew Peak, Mark A Turner, Rosalind L Smyth, Anthony J Nunn, Munir Pirmohamed

Abstract

Background: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs.

Methods: A nested case?control study was conducted within a prospective cohort study. Details of all medicines administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring.

Results: A total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval (CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82 to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3 95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard (HR 1.2 95% CI 1.2 to 1.3, P <0.001).

Conclusions: OLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs.

References

    1. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91:755–758. doi: 10.1038/clpt.2012.37.
    1. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5:703–718. doi: 10.1517/14740338.5.5.703.
    1. The European Parliament and the Council of the European Union. Regulation (EC) no 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union. 2006;49:1–19.
    1. S. 650--108th Congress. Pediatric Research Equity Act of 2003. 2003. (Accessed 4 March 2013)
    1. Turner S, Nunn A, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999;88:965–968. doi: 10.1111/j.1651-2227.1999.tb00191.x.
    1. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol. 2012;68:21–28. doi: 10.1007/s00228-011-1097-1.
    1. Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, Turner MA, Smyth RL, Pirmohamed M. Development and inter-rater reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool. PLoS One. 2011;6:e28096. doi: 10.1371/journal.pone.0028096.
    1. DataPharm Communications Ltd. Electronic Medicines Compendium. . (Accessed 4 March2013)
    1. Paediatric Formulary Committee. BNF for Children. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2009/2010.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, G?tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349. doi: 10.1016/j.jclinepi.2007.11.008.
    1. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, Rocchi F, Bonati M, TJong G, de Hoog M, van den Anker J. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000;320:79–82. doi: 10.1136/bmj.320.7227.79.
    1. Jong GWT, Vulto AG, De Hoog M, Schimmel KJM, Tibboel D, Van Den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics. 2001;108:1089–1093. doi: 10.1542/peds.108.5.1089.
    1. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, Brune K, Hinz B. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27:1059–1067. doi: 10.2165/00002018-200427130-00006.
    1. Santos D, Clavenna A, Bonati M, Coelho H. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008;64:1111–1118. doi: 10.1007/s00228-008-0543-1.
    1. van den Bemt PMLA, Egberts ACG, Lenderink AW, Verzijl JM, Simons KA, van der Pol WSCJM, Leufkens HGM. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22:62–66. doi: 10.1023/A:1008721321016.
    1. Camargo A, Cardoso Ferreira M, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol. 2006;62:143–149. doi: 10.1007/s00228-005-0086-7.
    1. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4:e4439. doi: 10.1371/journal.pone.0004439.
    1. Epstein RS, Huang S. The many sides of off-label prescribing. Clin Pharmacol Ther. 2012;91:755–758. doi: 10.1038/clpt.2012.37.
    1. Knibbe CAJ, Krekels EHJ, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol. 2011;7:1–8. doi: 10.1517/17425255.2011.539201.
    1. Richey RH, Shah UU, Peak M, Craig JV, Ford JL, Barker CE, Nunn AJ, Turner MA. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr. 2013;13:81. doi: 10.1186/1471-2431-13-81.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다